Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790 · View on ClinicalTrials.gov ↗
Study Summary
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rusfertide
Study Locations (20)
California
- City of Hope Medical Center, Duarte — Duarte
- California Cancer Associates for Research and Excellence - Fresno — Fresno
- Marin Cancer Care — Greenbrae
- City of Hope Medical Center, Lenner — Irvine
- University of California, San Diego (UCSD) - Moores Cancer Center — La Jolla
- University of California, Los Angeles (UCLA) - Medical Center — Los Angeles
- Stanford University — Palo Alto
- Pomona Valley Hospital Medical Center — Pomona
- Sharp Memorial Hospital — San Diego
- University of California, San Francisco — San Francisco
- City of Hope Medical Center, Upland — Upland
Colorado
- Rocky Mountain Cancer Centers — Aurora
- University of Colorado - Aurora Cancer Center — Aurora
- Rocky Mountain Cancer Centers - Boulder — Boulder
- Rocky Mountain Cancer Centers — Colorado Springs
- Rocky Mountain Cancer Centers — Colorado Springs
- Rocky Mountain Cancer Centers — Denver
- Rocky Mountain Cancer Centers — Lakewood
Alabama
- Infirmary Cancer Care — Mobile
Arizona
- Palo Verde Hematology-Oncology — Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05210790
The ClinicalTrials.gov registry entry for NCT05210790 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protagonist Therapeutics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Polycythemia Vera appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05210790 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Colorado, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05210790 about?
NCT05210790 is a clinical study titled "A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera". The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
What is the current status of trial NCT05210790?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 293 participants. The study started on 2022-04-01. Estimated completion is 2027-06.
What conditions does trial NCT05210790 study?
This clinical trial studies the following conditions: Polycythemia Vera. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05210790?
The interventions under investigation include: Placebo (DRUG), Rusfertide (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05210790?
This trial is sponsored by Protagonist Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05210790 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.